AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05848661 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.
Study NCT05312008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
Study NCT05312008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
Study NCT05537545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue grafting
Description: A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
Study NCT05537545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue grafting
Description: A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
Study NCT06124235 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles
Description: insertion:~1. According to the random number generated, the corresponding envelop for left and right side by chosen.~2. The patient will be asked to brush his/her teeth.~3. The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~1. The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~2. Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~3. OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~4. x-ray will be taken to confirm OMS position.
Study NCT06124235 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles
Description: Non-coated orthodontic miniscrews
Study NCT06573970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
Study NCT06573970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
Study NCT06229912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given by PO
Study NCT05515185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT095 CAR-T injection
Description: Clearance of lymphocytes
Study NCT05125601 — intervention group
Intervention type: OTHER
Intervention: The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)
Description: The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
Study NCT05649228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study NCT05649228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin 0.1% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study NCT05649228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Palmitate 0.25% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study NCT05649228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin Palmitate 0.25% Cream
Description: A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study NCT05649228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study NCT05649228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cream
Description: A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study NCT05279482 — intervention group
Intervention type: OTHER
Intervention: observation for outcome of methylprednisolone dose
Description: no intervention as it is retrospective study for outcome
Study NCT04086030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.
Study NCT04086030 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Flow Restriction Training
Description: Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
Study NCT04625413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: UR-GOAL communication tool
Description: The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
Study NCT05106465 — intervention group
Intervention type: DEVICE
Intervention: Konectom platform
Description: Administered as specified in the treatment arm.
Study NCT06677190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
Study NCT05083221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hear-Talk-Activity audiological program
Description: The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
Study NCT03806439 — intervention group
Intervention type: OTHER
Intervention: Radical cystectomy.
Description: Adult patients undergoing radical cystectomy.
Study NCT05763238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERVENTION GROUP
Description: Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup
Study NCT05763238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup
Study NCT03226626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD
Description: Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
Study NCT03226626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD
Description: Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
Study NCT03226626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SubQKath
Description: The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
Study NCT06257914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Catquest-9SF
Description: Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
Study NCT05007353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Lifestyle Intervention
Description: Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
Study NCT05007353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided Intervention
Description: In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
Study NCT05062057 — intervention group
Intervention type: DEVICE
Intervention: Adhesive ambulatory ECG recording patches
Description: All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Gradual shortening of infusion times
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Gradual shortening of infusion times
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Gradual shortening of infusion times
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Gradual shortening of infusion times
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Gradual shortening of infusion times
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Gradual shortening of infusion times
Study NCT06031233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Gradual shortening of infusion times
Study NCT06226363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNF1901 Monoclonal Antibody Injection
Description: LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
Study NCT05825690 — intervention group
Intervention type: OTHER
Intervention: Retrospective evaluation of specific brain MRI features
Description: Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry
Study NCT05162092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.
Study NCT05162092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation with conventional physiotherapy
Description: Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
Study NCT05497726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection using intravenous bevacizumab-800CW
Description: Sentinel lymph node detection using intravenous bevacizumab-800CW
Study NCT05281263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPI-RSV-F Vaccine (BLB-201)
Description: see arm/group description
Study NCT04530162 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound guided nerve block
Description: nerve block using bupivacaine and dexamethasone.
Study NCT05779709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
Study NCT05779709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
Study NCT06120257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lithotripsy using Flexible ureteroscope
Description: using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
Study NCT06120257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave lithotripsy (ESWL)
Description: using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
Study NCT06120257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holmium laser lithotripsy using Karl® Storz MIP set
Description: using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
Study NCT04671836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 1Mg Tablet
Description: 1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.
Study NCT04671836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam 1Mg Tablet
Description: 1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.
Study NCT04671836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
Study NCT04671836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
Study NCT05043584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam LX, Fluoptics, Grenoble, France
Description: See arm description
Study NCT05671276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and clopidogrel
Description: DAPT (until 6 months) + ASA
Study NCT05671276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: half-dose NOAC
Study NCT06261671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antioxidants-enriched culture medium (Gx)
Description: Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
Study NCT06248853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garston technique
Description: the patients will receive instrumented assisted soft tissue mobilization using the Graston technique, which includes the application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin. The Graston tools will be used to mobilize the tissues of the triceps surae and plantar foot bypassing the tools along the leg and foot
Study NCT06248853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
Study NCT05095025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 20ml injectate
Description: Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
Study NCT05295537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PERCUTANEOUS LIVER BIOPSY (PLB)
Description: Percutaneous liver biopsy using a 16 gauge (G) Trucut needle.
Study NCT05295537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS-LB)
Description: EUS-guided liver biopsy using a 19 gauge (G) Franseen core EUS needle
Study NCT06248853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
Study NCT05735639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin Sodium
Description: Low molecular weight heparin
Study NCT05735639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Sodium
Description: Low molecular weight heparin
Study NCT05735639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium
Description: Low molecular weight heparin
Study NCT05735639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Direct oral anticoagulant
Study NCT05735639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Direct oral anticoagulant
Study NCT05735639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Direct oral anticoagulant